Roche UBE3A Angelman Syndrome Oligonucleotide Patent Granted

USPTO granted patent US12596118B2 to Hoffmann-La Roche Inc. covering oligonucleotides capable of inducing paternal UBE3A expression for treatment of Angelman syndrome. The patent, listing 9 inventors, contains 30 claims targeting the SNHG14 long non-coding RNA downstream of SNORD109B. This is a pharmaceutical composition patent within the oligonucleotides therapeutic space.

DISARM Therapeutics patent, SARM1 inhibitors, neuroprotection

DISARM Therapeutics patent, SARM1 inhibitors, neuroprotection

Treatment of tumors with miRNA targeting CDK4/CDK6

USPTO granted patent US12595483B2 to the Institute for Cancer Research of Fox Chase Cancer Center for miRNA mimics targeting CDK4 and/or CDK6 for tumor treatment, including colon cancer. The patent covers modified oligonucleotides comprising miRNA and methods for administering the compositions to patients.

Vasopressin-2 receptor antagonist peptides and uses thereof

The USPTO has granted Patent US12595288B2 to Commissariat à l'Énergie Atomique et aux Énergies Alternatives covering vasopressin-2 receptor antagonist peptides. The patent protects peptide sequences with at least 80% amino acid identity to SEQ ID NO. 1, with specific modifications at variable positions enabling therapeutic applications. The grant includes 14 claims.

Methods to Decrease Impurities from Recombinant Protein Manufacturing Processes

The USPTO granted Patent US12595294B2 to Hoffmann-La Roche Inc. on April 7, 2026. The patent covers methods for reducing non-aggregate produce-related impurities (NAPRIs) in buffered solutions of monoclonal antibodies using synthetic depth filters. Inventors are Marc Pompiati and Christoph Feistl, with 15 claims in the granted patent.

Anti-NGF Antibody and Antigen-Binding Fragment Patent Grant

USPTO granted Patent US12595298B2 to XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD. for an anti-NGF antibody and its antigen-binding fragment, covering the preparation method and therapeutic applications for NGF-mediated diseases. The patent includes 6 claims and was filed on August 2, 2021.

Fc Variants and IL-8 Antibodies Patent Grant

USPTO granted patent US12595299B2 to Chugai Seiyaku Kabushiki Kaisha covering Fc region variants with improved antigen binding in ion concentration-dependent manner, Fc variants with decreased binding to pre-existing anti-drug antibodies, and novel IL-8 antibodies for pharmaceutical use. The patent contains 17 claims and covers molecules derived from antibody engineering technology.

Anti-human P40 protein domain antibody and use thereof

USPTO granted Patent US12595300B2 to Akeso Biopharma, Inc. covering an anti-human P40 protein domain antibody for treating autoimmune diseases. The patent includes 20 claims with specific amino acid sequences for heavy and light chain variable regions (SEQ ID NOs 1, 24 for heavy chain; SEQ ID NOs 6, 11, 13, 15, 17, 25 for light chain).

LMP-1 Expressing Cells and Methods of Use Thereof - Dana-Farber Cancer Institute

Dana-Farber Cancer Institute, Inc. has been granted USPTO Patent US12595285B2 covering immunogenic cells expressing LMP1 and methods of use for cancer treatment and T cell activation. The patent, with 15 claims, names Baochun Zhang, Il-Kyu Choi, and Zhe Wang as inventors, with an application filing date of May 13, 2022.

P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims

P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims